AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
Thu 22 May 25, 01:18 PMFiring on All Cylinders: CONMED (NYSE:CNMD) Q1 Earnings Lead the Way
Tue 20 May 25, 03:35 AMBD Stock May Rise Following the Launch of FACSDiscover A8 Platform
Mon 19 May 25, 02:12 PMBecton Dickinson (NYSE:BDX) Unveils Advanced Cell Analyzer With Spectral And Imaging Innovations
Wed 14 May 25, 05:32 PMFirst Eagle Investment's Strategic Moves: Spotlight on Becton Dickinson & Co
Mon 12 May 25, 09:02 PM| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | 1882.00M | 2005.00M | 1662.00M | 1783.00M | 2242.00M |
| Minority interest | - | - | - | - | - |
| Net income | 1678.00M | 1705.00M | 1484.00M | 1779.00M | 2092.00M |
| Selling general administrative | 5278.00M | 4857.00M | 4719.00M | 4709.00M | 1.00M |
| Selling and marketing expenses | - | - | - | - | 4867.00M |
| Gross profit | 9924.00M | 9125.00M | 8170.00M | 8477.00M | 9427.00M |
| Reconciled depreciation | 2462.00M | 2286.00M | 2288.00M | 2229.00M | 2273.00M |
| Ebit | 2495.00M | 2533.00M | 2427.00M | 2282.00M | 2799.00M |
| Ebitda | 4957.00M | 4819.00M | 4715.00M | 4602.00M | 5169.00M |
| Depreciation and amortization | 2462.00M | 2286.00M | 2288.00M | 2320.00M | 2370.00M |
| Non operating income net other | - | - | - | -101.00000M | -88.00000M |
| Operating income | 2578.00M | 2397.00M | 2111.00M | 2282.00M | 2799.00M |
| Other operating expenses | 19262.00M | 17781.00M | 16948.00M | 16395.00M | 17265.00M |
| Interest expense | 613.00M | 528.00M | 452.00M | 398.00M | 469.00M |
| Tax provision | 203.00M | 300.00M | 132.00M | 148.00M | 150.00M |
| Interest income | 38.00M | 163.00M | 49.00M | 16.00M | 460.00M |
| Net interest income | -575.00000M | -365.00000M | -403.00000M | -382.00000M | -460.00000M |
| Extraordinary items | 0.00000M | 0.00000M | -46.00000M | 144.00M | 488.00M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 204.00M | 300.00M | 132.00M | 148.00M | 150.00M |
| Total revenue | 21839.00M | 20178.00M | 19372.00M | 18870.00M | 20248.00M |
| Total operating expenses | 7347.00M | 6728.00M | 5746.00M | 6002.00M | 6444.00M |
| Cost of revenue | 11915.00M | 11053.00M | 11202.00M | 10393.00M | 10821.00M |
| Total other income expense net | -696.00000M | -392.00000M | -359.00000M | -499.00000M | -557.00000M |
| Discontinued operations | - | - | - | 144.00M | 144.00M |
| Net income from continuing ops | 1678.00M | 1705.00M | 1530.00M | 1635.00M | 2092.00M |
| Net income applicable to common shares | 1678.00M | 1705.00M | 1424.00M | 1689.00M | 2002.00M |
| Preferred stock and other adjustments | - | - | - | 90.00M | 90.00M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 55325.00M | 57286.00M | 52780.00M | 52934.00M | 53866.00M |
| Intangible assets | 2994.00M | 10917.00M | 552.00M | 12311.00M | 12784.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1508.00M | 1291.00M | 1380.00M | 1712.00M | 1071.00M |
| Total liab | 29936.00M | 31397.00M | 26984.00M | 27633.00M | 30189.00M |
| Total stockholder equity | 25390.00M | 25911.00M | 25796.00M | 25301.00M | 23677.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 4779.00M | 4722.00M | 5500.00M | 3933.00M | 6126.00M |
| Common stock | 371.00M | 371.00M | 371.00M | 365.00M | 365.00M |
| Capital stock | 371.00M | - | - | 367.00M | 367.00M |
| Retained earnings | 16622.00M | 16139.00M | 15535.00M | 15157.00M | 13826.00M |
| Other liab | - | - | - | 5936.00M | 6453.00M |
| Good will | 33023.00M | 26465.00M | 24522.00M | 24621.00M | 23901.00M |
| Other assets | 2171.00M | - | 2078.00M | 1.00M | -1.00000M |
| Cash | 851.00M | 1856.00M | 1416.00M | 1006.00M | 2283.00M |
| Cash and equivalents | 641.00M | - | 1416.00M | 1006.00M | 2283.00M |
| Total current liabilities | 8313.00M | 8956.00M | 6641.00M | 7811.00M | 6626.00M |
| Current deferred revenue | - | - | -1641.00000M | - | -1793.00000M |
| Net debt | 18330.00M | 18254.00M | 14463.00M | 15059.00M | 15327.00M |
| Short term debt | 1560.00M | 2170.00M | 1141.00M | 2179.00M | 500.00M |
| Short long term debt | 1560.00M | - | 1141.00M | 2179.00M | 500.00M |
| Short long term debt total | 19181.00M | 20110.00M | 15879.00M | 16065.00M | 17610.00M |
| Other stockholder equity | 10292.00M | 9401.00M | 11438.00M | 11265.00M | 11572.00M |
| Property plant equipment | 7882.00M | - | 6557.00M | 6012.00M | 6393.00M |
| Total current assets | 9255.00M | 10468.00M | 8676.00M | 8141.00M | 8838.00M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | -11631.00000M | -13007.00000M |
| Short term investments | 8.00M | 445.00M | 8.00M | 8.00M | 12.00M |
| Net receivables | 2994.00M | 3033.00M | 2534.00M | 2191.00M | 2497.00M |
| Long term debt | 17621.00M | - | 14738.00M | 13886.00M | 17110.00M |
| Inventory | 3894.00M | 3843.00M | 3273.00M | 3224.00M | 2866.00M |
| Accounts payable | 1974.00M | 1896.00M | 1641.00M | 1699.00M | 1793.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1870.00000M | - | -1548.00000M | -1488.00000M | -2088.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 365.00M | 365.00M |
| Preferred stock total equity | - | - | - | 2.00M | 2.00M |
| Retained earnings total equity | - | - | - | 15157.00M | 13826.00M |
| Treasury stock | - | - | - | -8330.00000M | -7723.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3056.00M | 2615.00M | 2078.00M | -3361.00000M | 1952.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 46070.00M | 46818.00M | 44104.00M | 44792.00M | 45029.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 17621.00M | - | 14738.00M | 13886.00M | 17110.00M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | -818.00000M | - | -716.00000M | -3231.00000M | -1880.00000M |
| Change to liabilities | - | - | -517.00000M | -473.00000M | 687.00M |
| Total cashflows from investing activities | -818.00000M | - | -716.00000M | -3220.00000M | -1880.00000M |
| Net borrowings | -1334.00000M | - | -723.00000M | -78.00000M | -243.00000M |
| Total cash from financing activities | -3617.00000M | 2087.00M | -1957.00000M | -591.00000M | -3306.00000M |
| Change to operating activities | - | - | 192.00M | -1394.00000M | 282.00M |
| Net income | 1678.00M | 1705.00M | 1530.00M | 1779.00M | 2092.00M |
| Change in cash | -1005.00000M | 375.00M | 322.00M | -1233.00000M | -525.00000M |
| Begin period cash flow | 1856.00M | 1481.00M | 1159.00M | 2392.00M | 2917.00M |
| End period cash flow | 851.00M | 1856.00M | 1481.00M | 1159.00M | 2392.00M |
| Total cash from operating activities | 3430.00M | 3844.00M | 2989.00M | 2633.00M | 4647.00M |
| Issuance of capital stock | - | - | - | 0.00000M | 0.00000M |
| Depreciation | 2462.00M | 2286.00M | 2288.00M | 2229.00M | 2273.00M |
| Other cashflows from investing activities | -480.00000M | - | 158.00M | -177.00000M | -141.00000M |
| Dividends paid | 1196.00M | 1100.00M | 1114.00M | 1082.00M | 1048.00M |
| Change to inventory | -410.00000M | 98.00M | -15.00000M | -631.00000M | -104.00000M |
| Change to account receivables | 71.00M | - | -290.00000M | 32.00M | -95.00000M |
| Sale purchase of stock | -1000.00000M | -500.00000M | 0.00000M | -500.00000M | -1750.00000M |
| Other cashflows from financing activities | -87.00000M | -88.00000M | 1312.00M | 1796.00M | -265.00000M |
| Change to netincome | - | - | -153.00000M | 155.00M | -20.00000M |
| Capital expenditures | 760.00M | 725.00M | 874.00M | 973.00M | 1231.00M |
| Change receivables | - | - | - | 32.00M | -95.00000M |
| Cash flows other operating | - | - | - | 1180.00M | -515.00000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -1485.00000M | -539.00000M |
| Change in working capital | -800.00000M | - | -828.00000M | -1394.00000M | 282.00M |
| Stock based compensation | 258.00M | 247.00M | 259.00M | 233.00M | 237.00M |
| Other non cash items | 306.00M | -183.00000M | 362.00M | -94.00000M | 67.00M |
| Free cash flow | 2670.00M | 3119.00M | 2115.00M | 1660.00M | 3416.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BDX Becton Dickinson and Company |
3.95 2.71% | 149.56 | 25.56 | 12.48 | 2.59 | 1.76 | 2.89 | 12.55 |
| ISRG Intuitive Surgical Inc |
11.53 2.83% | 418.82 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOF EssilorLuxottica Société anonyme |
- -% | 201.48 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
4.49 4.57% | 102.66 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| HOCPF HOYA Corporation |
- -% | 170.92 | 35.71 | - | 0.06 | 6.34 | 0.05 | 0.15 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care
1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas E. Polen Jr. | Pres, CEO & Chairman | 1973 |
| Mr. Christopher DelOrefice | Exec. VP & CFO | 1971 |
| Mr. Samrat S. Khichi Esq. | Exec. VP of Corp. Devel., Public Policy & Regulatory Affairs and Gen. Counsel | 1967 |
| Mr. Thomas J. Spoerel | Sr. VP, Controller & Chief Accounting Officer | 1978 |
| Ms. Elizabeth McCombs | Exec. VP & Chief Technology Officer | 1976 |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board | NA |
| Ms. Denise Fleming | Exec. VP of Technology & Global Services and Chief Information Officer | NA |
| Ms. Francesca M. DeMartino | Sr. VP & Head of Investor Relations | NA |
| Michelle Quinn | Sr. VP and Chief Ethics & Compliance Officer | NA |
| Troy Kirkpatrick | VP of PR | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...